Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
cardiogenic shock
MeSH D012770 - cardiogenic shock
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009203:
Myocardial infarction
172 Companies
45 Drugs
$
Success rate
D012769:
Shock
92 Companies
18 Drugs
$
Success rate
D012770:
Cardiogenic shock
24 Companies
4 Drugs
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Eli Lilly
Glucagon
Baqsimi
2019-12-16
$652.8 M
Q2/23-Q3/24
Glucagon
Glucagon
1982-01-01
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0
%
0/0
Phase 2
80
%
4/5
Phase 3
47
%
7/15
Approved:
4
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
GSK
Digoxin
Eli Lilly
Glucagon
,
Clotinab
,
Arm1
,
Bolus
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use